Daniel A. González-Padilla Profile picture
Urologist I Evidence-Based Medicine | Uro-Oncology | ⛩️ Leaders lead by example
Nov 9, 2022 15 tweets 6 min read
🛠️Surgical instruments used in #Urology

Part 2.

🧵 Asepto syringe

🇪🇸Jeringa Asepto
Nov 9, 2022 26 tweets 8 min read
🛠️Surgical instruments used in #Urology

It's important to know our instruments, most of them have eponymous names which pay tribute to surgical legends.

Here I will post pictures of instruments that every trainee should know (taken from different books):

@ResidentesAEU

1/🧵 Image Backhaus or Towel clamp

🇪🇸 Backhaus - Piel y campo. Image
Nov 29, 2021 12 tweets 6 min read
In this #UrologyJournalClub we discuss and summarize the Belzitufan Phase 2 trial for renal masses in patients with Von Hippel-Lindau (VHL) disease published @NEJM which led to the approval of Welireg.

🔗 pubmed.ncbi.nlm.nih.gov/34818478/

💾urologiabe.files.wordpress.com/2021/11/urolog…

1/

@VPrasadMDMPH ImageImageImage 📃 phase 2, single arm, open label
N=61

Pts with VHL and renal masses (assumed to be renal cell carcinoma, biopsy not required).

Most pts had other VHL-related tumors simultaneously but these were not considered for inclusion or exclusion criteria but measured either way.

2/ Image
May 7, 2020 8 tweets 3 min read
💡A few thoughts about the recently published PROfound trial “Olaparib for Metastatic Castration-Resistant Prostate Cancer” @ NEJM.

I decided to give a shot at critical lecture.

The first thing that draw my attention was the inclusion criteria.

#UroSoMe @VPrasadMDMPH

1/8 "men with confirmed M1 castration-resistant prostate cancer (CRPC) whose disease had progressed during treatment with enza or abi, administered for M1 or M0 CRPC or M1 hormone-sensitive prostate cancer. Previous taxane chemotherapy was allowed.”

Now look at control arm 👀

2/8